epirubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 217 Diseases   230 Trials   230 Trials   3979 News 


«12...3637383940414243444546...5051»
  • ||||||||||  Trial initiation date, Trial primary completion date:  ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 (clinicaltrials.gov) -  Nov 27, 2017   
    P2,  N=60, Not yet recruiting, 
    Initiation date: Oct 2017 --> Jan 2018 | Trial primary completion date: Sep 2027 --> Dec 2027
  • ||||||||||  Trial primary completion date:  Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) -  Nov 13, 2017   
    P3,  N=249, Completed, 
    Conclusion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and after radiotherapy. Trial primary completion date: Oct 2017 --> Feb 2017
  • ||||||||||  epirubicin / Generic mfg.
    Phase classification, Trial initiation date, Trial primary completion date:  TURBt With Adjuvant Cryoablation to Treat Bladder Cancer (clinicaltrials.gov) -  Oct 19, 2017   
    P=N/A,  N=150, Not yet recruiting, 
    Trial primary completion date: Sep 2018 --> Dec 2018 Phase classification: P2 --> P=N/A | Initiation date: Jun 2016 --> Oct 2017 | Trial primary completion date: Jun 2017 --> Oct 2018
  • ||||||||||  Ingavirin (imidazolyl ethanamide pentandioic acid) / Myelo Therap, Valenta Pharm
    Enrollment closed:  MyeloConcept: Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (clinicaltrials.gov) -  Oct 16, 2017   
    P2a,  N=137, Active, not recruiting, 
    Phase classification: P2 --> P=N/A | Initiation date: Jun 2016 --> Oct 2017 | Trial primary completion date: Jun 2017 --> Oct 2018 Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Ingavirin (imidazolyl ethanamide pentandioic acid) / Myelo Therap, Valenta Pharm
    Enrollment status:  MyeloConcept: Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (clinicaltrials.gov) -  Sep 27, 2017   
    P2a,  N=130, Enrolling by invitation, 
    Although the pCR percentage was comparable with chemotherapy regimens with trastuzumab alone the high RFS and OS are of interest in these high-risk populations. Recruiting --> Enrolling by invitation
  • ||||||||||  metformin / Generic mfg.
    Trial primary completion date:  NeoMET Study in Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) -  Sep 21, 2017   
    P2,  N=200, Recruiting, 
    Recruiting --> Enrolling by invitation Trial primary completion date: Dec 2017 --> Dec 2019
  • ||||||||||  Trial primary completion date:  Phase II Trial for Large ER-Negative Breast Cancers (clinicaltrials.gov) -  Sep 7, 2017   
    P2,  N=73, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Aug 2017 --> Dec 2009
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date, Metastases:  mEGA: Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (clinicaltrials.gov) -  Sep 1, 2017   
    P=N/A,  N=13, Terminated, 
    Active, not recruiting --> Completed | Phase classification: P2/3 --> P2 | N=370 --> 98 N=20 --> 13 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2016; Issues with recruitment.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. (Pubmed Central) -  Aug 9, 2017   
    Another validation cohort received FAC chemotherapy only, and a fifth cohort received concurrent trastuzumab (H) with sequential paclitaxel and fluorouracil, epirubicin, and cyclophosphamide (FEC; H+T/FEC)...Conclusion RCB was prognostic for long-term survival after neoadjuvant chemotherapy in all three phenotypic subsets of breast cancer. Our institutional findings should be externally validated.
  • ||||||||||  cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
    Trial primary completion date, Combination therapy, Metastases:  VPA-FEC100: Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer (clinicaltrials.gov) -  Jul 21, 2017   
    P2,  N=6, Terminated, 
    Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested. Trial primary completion date: Dec 2015 --> Dec 2010
  • ||||||||||  albumin-bound paclitaxel / Generic mfg.
    Enrollment closed:  GAIN-2: Study of Nab-Paclitaxel in High Risk Early Breast Cancer (clinicaltrials.gov) -  Jul 13, 2017   
    P3,  N=2886, Active, not recruiting, 
    Trial primary completion date: Apr 2022 --> Dec 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Trial primary completion date, Metastases:  Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) -  Jul 6, 2017   
    P2,  N=20, Recruiting, 
    Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2016 Trial primary completion date: Jun 2017 --> Jun 2018
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
    Biomarker, Retrospective data, Journal:  Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer. (Pubmed Central) -  Jun 28, 2017   
    In survival analysis, there were no differences in OS (P = .137) and DFS (P = .225) between the 2 groups.Adjuvant chemotherapy could provide little benefit to postmenopausal patients with luminal A, node-positive breast cancer, and endocrine therapy alone may help reduce morbidity. Future studies with a large number of patients and longer follow-up time are necessary to determine whether chemotherapy might be avoided in this patient population.